OptiBiotix Health PLC Non-exclusive distribution agreement for SlimBiome (7468C)
03 October 2018 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 7468C
OptiBiotix Health PLC
03 October 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Non-exclusive distribution agreement for SlimBiome(R)
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces it has entered into a non-exclusive
agreement with Formulation Creations ("Formulation") to distribute
OptiBiotix's SlimBiome(R) proprietary weight management technology
in South Africa.
Formulation is a fast-growing South African ingredient solutions
company, specialising in the formulation and supply of world class
flavour and ingredients into the food manufacturing, health and
sports nutrition sectors. They are the exclusive distributor in
South Africa for Gold Coast Ingredients, Real Stevia, and Cambridge
Commodities (OptiBiotix's UK distributor for SlimBiome(R)).
The agreement continues OptiBiotix's strategy of expanding
SlimBiome(R) and SlimBiome (R) related products; like its own brand
GoFigure(R) products; into global markets. South Africa represents
a new opportunity in a growing market where the latest South
African Demographic and Health Survey (2017) identified almost 70%
of South African women are either overweight or obese. SlimBiome(R)
is a patented formulation developed by experts in nutrition using
ingredients shown to reduce weight in human studies. Independent
human studies at a number of universities have shown SlimBiome(R)
reduces hunger and cravings for sweet, fatty and savoury foods,
leading to an average 2-3lb per week weight loss.
Formulation CEO Gary Coulson commented: "We are very excited to
be working with OptiBiotix within our local market. Their portfolio
of cutting-edge ingredients fits perfectly into our existing
product range and offering strategy. We look forward to marketing
their new science-based microbiome solutions to perspective health
and nutrition product manufacturers."
Christina Wood, Sales & Marketing Director of OptiBiotix
added: "Formulation is led by Gary Coulson, an industry expert with
an extensive network of customers and partners in the South African
market. With such a wealth of local knowledge and technical
expertise in the health and wellness sector, we are in a great
position to offer the South African market bespoke concepts and
weight management products to meet the demands of the local
population."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRGMMGGKZKGRZM
(END) Dow Jones Newswires
October 03, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024